Pharming To Branch Out Into Japan With Leniolisib Following Successful Pivotal Trial
The Dutch firm has announced its intention to submit US and EU filings for leniolisib and expand development into Japan after the candidate impressed in an ultra-rare disease study.
You may also be interested in...
Leniolisib has become the first product to be granted accelerated assessment status by the European Medicines Agency this year.
The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success of its sole product, Ruconest, in HAE.
The French firm has suspended the manufacturing of its COVID-19 vaccine, instead emphasizing its hopes in advanced Lyme disease and Chikungunya.